The study of olaparib in recurrent ovarian cancer patients
National Cancer Institute, Naples is recruiting patients for the clinical trial MITO 35b, which is designed as randomized, open label, phase III trial that aims to assess the efficacy of olaparib maintenance beyond progression compered to standard platinum-based chemotherapy after secondary cytoreductive surgery. The target population of this study are ovarian cancer patients who experience a disease recurrence or progression to a first line maintenance therapy with PARPi; at progression patients must have received a secondary cytoreduction according to clinical practice.
The researchers plan that January 21, 2022 will be the study start date. The indicative completion of the clinical trial will be expected in January 21, 2028.
Among primary outcome measures are the Progression-free survival (PFS) and PFS as defined by the Investigator using RECIST 1.1, as the time frame from randomization to progression or death for any cause,whichever comes first.
The study will take place at the IRCCS Istituto Nazionale Tumori di Napoli, Naples, Italy.
The page dedicated to this clinical trial can be found here: https://ichgcp.net/clinical-trials-registry/NCT05255471 or https://clinicaltrials.gov/ct2/show/NCT05255471?recrs=ab&type=Intr&sfpd_s=02%2F23%2F2022&draw=2&rank=14.
